Literature DB >> 26453937

Heterogeneity between triple negative breast cancer cells due to differential activation of Wnt and PI3K/AKT pathways.

Gabriela Martínez-Revollar1, Erika Garay2, Dolores Martin-Tapia1, Porfirio Nava1, Miriam Huerta3, Esther Lopez-Bayghen4, Noemí Meraz-Cruz5, José Segovia1, Lorenza González-Mariscal6.   

Abstract

The lack of a successful treatment for triple-negative breast cancer demands the study of the heterogeneity of cells that constitute these tumors. With this aim, two clones from triple negative breast MDA-MB-231 cancer cells were isolated: One with fibroblast-like appearance (F) and another with semi-epithelial (SE) morphology. Cells of the F clone have a higher migration and tumorigenesis capacity than SE cells, suggesting that these cells are in a more advanced stage of epithelial to mesenchymal transformation. In agreement, F cells have a diminished expression of the tight junction proteins claudins 1 and 4, and an increased content of β-catenin. The latter is due to an augmented activity of the canonical Wnt route and of the EGFR/PI3K/mTORC2/AKT pathway favoring the cytoplasmic accumulation of β-catenin and its transcriptional activity. In addition, F cells display increased phosphorylation of β-catenin at Tyr654 by Src. These changes favor in F cells, the over-expression of Snail that promotes EMT. Finally, we observe that both F and SE cells display markers of cancer stem cells, which are more abundant in the F clone.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AKT; Cancer cells heterogeneity; Triple negative breast cancer; Wnt; β-catenin

Mesh:

Substances:

Year:  2015        PMID: 26453937     DOI: 10.1016/j.yexcr.2015.10.006

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Precise targeting of cancer metastasis using multi-ligand nanoparticles incorporating four different ligands.

Authors:  P M Peiris; F He; G Covarrubias; S Raghunathan; O Turan; M Lorkowski; B Gnanasambandam; C Wu; W P Schiemann; E Karathanasis
Journal:  Nanoscale       Date:  2018-04-19       Impact factor: 7.790

2.  Short-term cellular memory tunes the signaling responses of the chemokine receptor CXCR4.

Authors:  Phillip C Spinosa; Brock A Humphries; Daniela Lewin Mejia; Johanna M Buschhaus; Jennifer J Linderman; Gary D Luker; Kathryn E Luker
Journal:  Sci Signal       Date:  2019-07-09       Impact factor: 8.192

Review 3.  Regulation of cancer stem cells in triple negative breast cancer.

Authors:  Norman Fultang; Madhuparna Chakraborty; Bela Peethambaran
Journal:  Cancer Drug Resist       Date:  2021-06-19

4.  Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.

Authors:  Mateusz Opyrchal; Malgorzata Gil; Jeffrey L Salisbury; Mathew P Goetz; Vera Suman; Amy Degnim; James McCubrey; Tufia Haddad; Ianko Iankov; Chenye B Kurokawa; Nicole Shumacher; James N Ingle; Evanthia Galanis; Antonino B D'Assoro
Journal:  Oncotarget       Date:  2017-09-01

Review 5.  Understanding cell signaling in cancer stem cells for targeted therapy - can phosphoproteomics help to reveal the secrets?

Authors:  Wolfgang Gruber; Tamara Scheidt; Fritz Aberger; Christian G Huber
Journal:  Cell Commun Signal       Date:  2017-03-29       Impact factor: 5.712

Review 6.  Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer.

Authors:  Qinqin Li; Zhenghuan Rao; Yanlin Wang; Lei Zhang; Jing Chen; Runlan Wan; Alexander Tobias Teichmann
Journal:  Cancer Cell Int       Date:  2021-06-10       Impact factor: 5.722

7.  Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.

Authors:  Pradip De; Jennifer H Carlson; Hui Wu; Adam Marcus; Brian Leyland-Jones; Nandini Dey
Journal:  Oncotarget       Date:  2016-07-12

8.  Imaging breast cancer using a dual-ligand nanochain particle.

Authors:  Gil Covarrubias; Anthony Cha; Abdelrahman Rahmy; Morgan Lorkowski; Vindya Perera; Bernadette O Erokwu; Chris Flask; Pubudu M Peiris; William P Schiemann; Efstathios Karathanasis
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.